Kurtan Yüksel, M. Et Al. 2019. Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.. ISTANBUL JOURNAL OF PHARMACY , vol.49, no.2 , 64-69.

Kurtan Yüksel, M., Öztürk, D., ÖZTAŞ, E., ÖZHAN, G., Altanlar Türker, A., Korkmaz, T., ... OKYAR, A.(2019). Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.. ISTANBUL JOURNAL OF PHARMACY , vol.49, no.2, 64-69.

Kurtan Yüksel, Merve Et Al. "Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.," ISTANBUL JOURNAL OF PHARMACY , vol.49, no.2, 64-69, 2019

Kurtan Yüksel, Merve K. Et Al. "Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.." ISTANBUL JOURNAL OF PHARMACY , vol.49, no.2, pp.64-69, 2019

Kurtan Yüksel, M. Et Al. (2019) . "Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.." ISTANBUL JOURNAL OF PHARMACY , vol.49, no.2, pp.64-69.

@article{article, author={Merve Kurtan Yüksel Et Al. }, title={Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients.}, journal={ISTANBUL JOURNAL OF PHARMACY}, year=2019, pages={64-69} }